Systemic influence of immunosuppressive drugs on small and large bowel transport and barrier function

Transplant International

Volumn 24, Issue 2, 2011, Pages 184-193

  Malinowski, MacIej ^a   Martus, Peter ^a   Lock, Johan Friso ^a   Neuhaus, Peter ^a   Stockmann, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

diarrhea; gastrointestinal disorders; immunosuppressive drugs; Ussing chamber

Indexed keywords

CHLORIDE; CYCLOSPORIN A; EVEROLIMUS; FINGOLIMOD; GLUCOSE; IMMUNOSUPPRESSIVE AGENT; LACTULOSE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; SODIUM; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DESCENDING COLON; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG TRANSPORT; GLUCOSE ABSORPTION; INTESTINE ABSORPTION; INTESTINE FUNCTION; ION CURRENT; LARGE INTESTINE; LOW DRUG DOSE; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SMALL INTESTINE; SODIUM ABSORPTION; WISTAR RAT;

ANIMALS; BIOLOGICAL TRANSPORT; CYCLOSPORINE; DIARRHEA; GLUCOSE; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; INTESTINE, LARGE; INTESTINE, SMALL; MALE; MYCOPHENOLIC ACID; PROPYLENE GLYCOLS; RATS; RATS, WISTAR; SIROLIMUS; SPHINGOSINE; TACROLIMUS;

EID: 78651096596     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01167.x     Document Type: Article

References (57)

1. Taylor AL, Watson CJ, Bradley JA,. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 2005; 56: 23.
2. Bunnapradist S, Neri L, Wong W, et al. Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality. Am J Kidney Dis 2008; 51: 478.
3. Dias VC, Madsen KL, Mulder KE, Keelan M, Yatscoff RW, Thomson AB,. Oral administration of rapamycin and cyclosporine differentially alter intestinal function in rabbits. Dig Dis Sci 1998; 43: 2227.
4. Helliwell PA, Rumsby MG, Kellett GL,. Intestinal sugar absorption is regulated by phosphorylation and turnover of protein kinase C betaII mediated by phosphatidylinositol 3-kinase- and mammalian target of rapamycin-dependent pathways. J Biol Chem 2003; 278: 28644.
5. Sigalet DL, Kneteman NM, Thomson AB,. The effects of cyclosporine on normal bowel. Transplantation 1991; 51: 1296.
6. Dias VC, Madsen KL, Yatscoff RW, Doring K, Thomson AB,. Orally administered immunosuppressants modify intestinal uptake of nutrients in rabbits. Transplantation 1994; 58: 1241.
7. Malinowski M, Martus P, Neuhaus P, Stockmann M,. The influence of commonly used immunosuppressive drugs on the small bowel functions-a comparative experimental study. Ann Transplant 2009; 14: 38.
8. Nielsen FT, Ottosen P, Starklint H, Dieperink H,. Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat. Nephrol Dial Transplant 2003; 18: 491.
9. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36.
10. Heller T, Geide A, Bonitz U, et al. Effect of the antioxidant idebenone on adverse events under mycophenolate mofetil therapy in a rat model. Transplantation 2008; 85: 739.
11. Takeichi T, Uemoto S, Minamiguchi S, et al. Effect of ONO-4057 and tacrolimus on ischemia-reperfusion injury of the liver. World J Gastroenterol 2009; 15: 5712.
12. Fuller TF, Hoff U, Kong L, et al. Cytoprotective actions of FTY720 modulate severe preservation reperfusion injury in rat renal transplants. Transplantation 2010; 89: 402.
13. Schulzke JD, Fromm M, Hegel U,. Epithelial and subepithelial resistance of rat large intestine: segmental differences, effect of stripping, time course, and action of aldosterone. Pflugers Arch 1986; 407: 632.
14. Stockmann M, Schmitz H, Fromm M, et al. Mechanisms of epithelial barrier impairment in HIV infection. Ann N Y Acad Sci 2000; 915: 293.
15. Wright EM, Loo DD,. Coupling between Na+, sugar, and water transport across the intestine. Ann N Y Acad Sci 2000; 915: 54.
16. Kroesen AJ, Stockmann M, Ransco C, Schulzke JD, Fromm M, Buhr HJ,. Impairment of epithelial transport but not of barrier function in idiopathic pouchitis after ulcerative colitis. Gut 2002; 50: 821.
17. Tai YH, Tai CY,. The conventional short-circuiting technique under-short-circuits most epithelia. J Membr Biol 1981; 59: 173.
18. Van Itallie CM, Anderson JM,. Molecular structure and regulation of tight junctions. Current Topics in Membranes. New Haven: Academic Press, 2001.
19. Schultz SG, Zalusky R,. Ion transport in isolated rabbit ileum I. Short-circuit current and Na fluxes. J Gen Physiol 1964; 47: 567.
20. Helliwell PA, Kellett GL,. The active and passive components of glucose absorption in rat jejunum under low and high perfusion stress. J Physiol 2002; 544: 579.
21. Fromm M, Schulzke JD, Hegel U,. Control of electrogenic Na+ absorption in rat late distal colon by nanomolar aldostreone added in vitro. Am J Physiol 1993; 264: E68.
22. Amasheh S, Barmeyer C, Koch CS, et al. Cytokine-dependent transcriptional down-regulation of epithelial sodium channel in ulcerative colitis. Gastroenterology 2004; 126: 1711.
23. Ussing HH, Zerahn K,. Active transport of sodium as the source of electric current in the short-circuited isolated frog skin. Acta Phys Scand 1951; 23: 110.
24. Fasano A, Baudry B, Pumplin DW,. Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci USA 1991; 88: 5242.
25. Blouquit S, Regnier A, Dannhoffer L, et al. Ion and fluid transport properties of small airways in cystic fibrosis. Am J Respir Crit Care Med 2006; 174: 299.
26. Hamilton KL, Kiessling M,. DCEBIO stimulates Cl- secretion in the mouse jejunum. Am J Physiol Cell Physiol 2006; 290: C152.
27. Gabe SM, Bjarnason I, Tolou-Ghamari Z, et al. The effect of tacrolimus (FK506) on intestinal barrier function and cellular energy production in humans. Gastroenterology 1998; 115: 67.
28. Madsen KL, Yanchar NL, Sigalet DL, Reigel T, Fedorak RN,. FK506 increases permeability in rat intestine by inhibiting mitochondrial function. Gastroenterology 1995; 109: 107.
29. Yanchar NL, Riegel TM, Martin G, Fedorak RN, Kneteman NM, Sigalet DL,. Tacrolimus (FK506)-its effects on intestinal glucose transport. Transplantation 1996; 61: 630.
30. Ginsburg PM, Thuluvath PJ,. Diarrhea in liver transplant recipients: etiology and management. Liver Transpl 2005; 11: 881.
31. Bhalla V, Hallows KR,. Mechanisms of ENaC regulation and clinical implications. J Am Soc Nephrol 2008; 19: 1845.
32. Kamar N, Oufroukhi L, Faure P, et al. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium. Nephrol Dial Transplant 2005; 20: 2231.
33. Chanda SM, Sellin JH, Torres CM, Yee JP,. Comparative gastrointestinal effects of mycophenolate mofetil capsules and enteric-coated tablets of sodium-mycophenolic acid in beagle dogs. Transplant Proc 2002; 34: 3387.
34. Darji P, Vijayaraghavan R, Thiagarajan CM, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders. Transplant Proc 2008; 40: 2262.
35. Shipkova M, Beck H, Voland A, et al. Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue. Proteomics 2004; 4: 2728.
36. Kamar N, Faure P, Dupuis E, et al. Villous atrophy induced by mycophenolate mofetil in renal-transplant patients. Transpl Int 2004; 17: 463.
37. Ducloux D, Ottignon Y, Semhoun-Ducloux S, et al. Mycophenolate mofetil-induced villous atrophy. Transplantation 1998; 66: 1115.
38. Segoloni GP, Quaglia M,. New immunosuppressive drugs for prevention and treatment of rejection in renal transplant. J Nephrol 2006; 19: 578.
39. Tedesco-Silva H, Mourad G, Kahan BD, et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 2004; 77: 1826.
40. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med 1994; 331: 1110.
41. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS,. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977.
42. Levy G, Villamil F, Samuel D, et al. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004; 77: 1632.
43. Cantarovich M, Tzimas GN, Barkun J, Deschenes M, Alpert E, Tchervenkov J,. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Transplantation 2003; 76: 98.
44. Pfitzmann R, Klupp J, Langrehr JM, et al. Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. Transplantation 2003; 76: 130.
45. EB R, CS M, JR S, et al. Mycophenolate mofetil versus enteric-coated mycophenolate sodium after simultaneous pancreas-kidney transplantation. Transplant Proc 2009; 41: 4265.
46. Sumethkul V, Na-Bangchang K, Kantachuvesiri S, Jirasiritham S,. Standard dose enteric-coated mycophenolate sodium (myfortic) delivers rapid therapeutic mycophenolic acid exposure in kidney transplant recipients. Transplant Proc 2005; 37: 861.
47. Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ,. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003; 9: 1079.
48. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140.
49. Moro JA, Almenar L, Martinez-Dolz L, Sanchez-Lazaro I, Aguero J, Salvador A,. Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation. Transplant Proc 2008; 40: 3034.
50. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26: 4311.
51. Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006; 12: 5165.
52. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124.
53. Maes BD, Dalle I, Geboes K, et al. Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation 2003; 75: 665.
54. Papadimitriou JC, Cangro CB, Lustberg A, et al. Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern. Int J Surg Pathol 2003; 11: 295.
55. Lingappa VR,. Gastrointestinal disease. In:, Nogueira I, ed. Pathophysiology of Disease, An Introduction to Clinical Medicine. Columbus: Lange Medical Books/McGraw-Hill, 2003: 340-380.
56. Bjarnason I, Macpherson A, Hollander D,. Intestinal permeability: an overview. Gastroenterology 1995; 108: 1566.
57. Guttman JA, Finlay BB,. Subcellular alterations that lead to diarrhea during bacterial pathogenesis. Trends Microbiol 2008; 16: 535.